Synthesis of new lipophilic acyclic di-ionizable polyethers, bis(crown ethers) and macrocyclic diamides
作者:Sadik Elshani、Chien M. Wai、N.R. Natale、Richard A. Bartsch
DOI:10.1016/s0040-4020(99)00514-1
日期:1999.7
A series of new lipophilic acyclic polyethers containing two carboxylic or hydroxamic acid groups have been prepared. From lipophilic acyclic polyether dicarboxylic acids 2, 9 and 13, the bis(crownethers) 20–25 were synthesized. From lipophilic acyclic polyether dicarboxylic acids 10–12 and 14, the new macrocyclic diamides 26–32 were prepared in high yields without the use of high dilution techniques
Peptide analog type-B CCK receptor ligands or pharmaceutically-acceptable salts thereof, which are useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and for the treatment of shock, respiratory and cardiocirculatory insufficiencies.
The present invention relates to a polyurethane polymer comprising as part of its polymer backbone an α-oxy carbonyl moiety of general formula (I), where A and B represent the remainder of the polymer backbone and are the same or different, and R is an optionally substituted aliphatic hydrocarbon having three or more carbon atoms.
Detergents are the most frequently applied reagents in membraneprotein (MP) studies. The limited diversity of one-head-one-tailed traditional detergents, however, is far from sufficient for structurally distinct MPs. Expansion of detergent repertoire has a continuous momentum. In line with the speculation that detergent pre-assembly exerts superiority, herein we report for the first time cross-conjugation
去污剂是膜蛋白 (MP) 研究中最常用的试剂。然而,一头一尾传统洗涤剂的有限多样性对于结构不同的 MP 来说还远远不够。洗涤剂品种的扩张势头不断。与去污剂预组装发挥优势的推测一致,本文首次报道了两个系列单体去污剂的交叉共轭,用于构建二聚去污剂的二维库。最佳去污剂在个体 MP 的系统评估中具有独特的偏好。此外,前所未有的混合去污剂 14M8G 和 14M9G 分别实现了转运蛋白 MsbA 的高质量 EM 研究和 G 蛋白偶联受体 A2A AR 的 NMR 研究。鉴于交叉偶联化学物质的丰富性,
Tetrapeptide type-B CCK receptor ligands
申请人:ABBOTT LABORATORIES
公开号:EP0405506A1
公开(公告)日:1991-01-02
A tetrapeptide type-B CCK receptor ligand of the formula
A-B-C-D
or a pharmaceutically acceptable salt thereof, which is useful for treating central nervous system disorders, substance abuse, gastrointestinal disorders, endocrine disorders, eating-related disorders and treatment of shock, respiratory and cardiocirculatory insufficiencies.